NEUMORA THERAPEUTICS, INC. Debt Securities, Available-for-sale, Unrealized Loss
NEUMORA THERAPEUTICS, INC. (NMRA) reported Debt Securities, Available-for-sale, Unrealized Loss of $0 for the 9-month period ending 2025-09-30, per its 10-Q filed 2025-11-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss · last filed 2026-03-30
- NEUMORA THERAPEUTICS, INC. debt securities, available-for-sale, unrealized loss for the quarter ending 2025-09-30 was -$15.00K.
- NEUMORA THERAPEUTICS, INC. debt securities, available-for-sale, unrealized loss for the quarter ending 2025-06-30 was $5.00K, a 83.87% decline year-over-year.
- NEUMORA THERAPEUTICS, INC. debt securities, available-for-sale, unrealized loss for the quarter ending 2025-03-31 was $10.00K, a 93.63% decline year-over-year.
- NEUMORA THERAPEUTICS, INC. debt securities, available-for-sale, unrealized loss for the quarter ending 2024-12-31 was -$1.00K.
- NEUMORA THERAPEUTICS, INC. debt securities, available-for-sale, unrealized loss for fiscal 2024 was $8.00K, a 92.16% decline from fiscal 2023.
- NEUMORA THERAPEUTICS, INC. debt securities, available-for-sale, unrealized loss for fiscal 2023 was $102.00K, a 86.84% decline from fiscal 2022.
- NEUMORA THERAPEUTICS, INC. debt securities, available-for-sale, unrealized loss for fiscal 2022 was $775.00K.
| Period end | Debt Securities, Available-for-sale, Unrealized Loss 3 month | Debt Securities, Available-for-sale, Unrealized Loss 6 month | Debt Securities, Available-for-sale, Unrealized Loss 9 month | Debt Securities, Available-for-sale, Unrealized Loss 12 month |
|---|---|---|---|---|
| 2025-09-30 | -$15.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$10.00K derived: sum of 2 quarters · filed 2025-11-06 | $0.00 10-Q · filed 2025-11-06 | -$1.00K derived: sum of 4 quarters · filed 2026-03-30 |
| 2025-06-30 | $5.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $15.00K 10-Q · filed 2025-08-06 | $14.00K derived: sum of 3 quarters · filed 2026-03-30 | -$165.00K derived: sum of 4 quarters · filed 2026-03-30 |
| 2025-03-31 | $10.00K 10-Q · filed 2025-05-12 | $9.00K derived: sum of 2 quarters · filed 2026-03-30 | -$170.00K derived: sum of 3 quarters · filed 2026-03-30 | -$139.00K derived: sum of 4 quarters · filed 2026-03-30 |
| 2024-12-31 | -$1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$180.00K derived: sum of 2 quarters · filed 2026-03-30 | -$149.00K derived: sum of 3 quarters · filed 2026-03-30 | $8.00K 10-K · filed 2026-03-30 |
| 2024-09-30 | -$179.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$148.00K derived: sum of 2 quarters · filed 2024-11-12 | $9.00K 10-Q · filed 2024-11-12 | -$206.00K derived: sum of 4 quarters · filed 2025-03-03 |
| 2024-06-30 | $31.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $188.00K 10-Q · filed 2024-08-06 | -$27.00K derived: sum of 3 quarters · filed 2025-03-03 | |
| 2024-03-31 | $157.00K 10-Q · filed 2024-05-07 | -$58.00K derived: sum of 2 quarters · filed 2025-03-03 | ||
| 2023-12-31 | -$215.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $102.00K 10-K · filed 2025-03-03 | ||
| 2023-09-30 | $317.00K 10-Q · filed 2023-11-01 | |||
| 2022-12-31 | $775.00K 10-K · filed 2024-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |